Neurodegenerative Disease - Patient Data Collection Technology Acceptability Study

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Regeneron Pharmaceuticals
Updated on 19 January 2023
Investigator
Roland Barge
Primary Contact
https://www.surveymonkey.co.uk/r/MJFF-UXR (online study) Contact
Online studies

Summary

You may be eligible to complete this 10-minute survey about your perceptions as a person who is at-risk for or has Parkinson disease (PD). This Research Survey is being conducted by Regeneron Pharmaceuticals, Inc. (REGN). The Survey asks for information about you and your views about clinical trial technologies. You are not expected to receive any direct benefit, but the information gained from your participation may help others in the future.

Please click on the online survey link to participate:

For any questions, concerns, complaints or research-related problems please contact the study team at 1-844-643-7346 (quoting project ID 22-UXR-A2). 

Description

You are free to complete the survey or not, or change your mind, without penalty or loss of benefits to which you are otherwise entitled. Responses are not saved until you click ‘next’ or the ‘submit’ button. Once submitted, REGN will be unable to delete your responses from the database as your responses are de-identified. This survey involves minimal risk, no more than using your computer or mobile device. If any questions make you uncomfortable, do not answer them. We do not collect your name or address, so the risk of loss of confidentiality is low. You are not expected to receive any direct benefit, but the information gained from your participation may help others in the future. Your alternative is to not participate in this survey.

Responses are protected via physical, electronic and procedural safeguards. They are collected via a secure website and stored on a password protected secure server at Survey Monkey & REGN for 10 years in accordance with REGN retention policy. The websites hosting the survey may have links to other websites that REGN have no control over and are not responsible for the content, privacy policies or security of any of these other websites you elect to visit or interact with.

Details
Condition Parkinson Disease, parkinson's disease, Parkinson's Disease
Clinical Study IdentifierTX310280
SponsorRegeneron Pharmaceuticals
Last Modified on19 January 2023

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note